Welcome to the home page of Tero Aittokallio's group Computational Systems Medicine in Cancer

Tero AittokallioGroup leader
Tero Aittokallio
Group leader

Our group has expertise in integrating multi-omics profiling and clinical information from cancer patients using mathematical and statistical approaches such as machine learning and network modeling. The medical aim is to optimize treatment outcomes for individual patients using maximally predictive models and minimal biomarker signatures that enable real-time and cost-effective routine diagnostics and prognosis. We believe that combining functional, molecular and genomic profiling information is critical for next-generation precision medicine applications, where integrative modeling and clever use of big data will pinpoint effective and selective targets for personalized therapies.

 

Projects

  • Multi-omics prediction of clinical outcomes for precision oncology applications
  • AI-guided treatment optimization by means of cost-effective biomarker panels
  • Decision support systems for real-time patient monitoring and adaptive trials

Selected Publications

  1. Ianevski A, Giri AK, Gautam P, Kononov A, Potdar S, Saarela J, Wennerberg K, Aittokallio T. Prediction of drug combination effects with a minimal set of experiments. Nature Machine Intelligence 2019. doi: 10.1038 / s42256-019-0122-4.
  2. He L, Tang J, Andersson EI, Timonen S, Koschmieder S, Wennerberg K, Mustjoki S, Aittokallio T. Patient-customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. Cancer Research 2018; 78 (9): 2407-2418. doi: 10.1158 / 0008-5472.CAN-17-3644.
  3. Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S , Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2017; 18 (1): 132-142. doi: 10.1016 / S1470-2045 (16) 30560-5.
  4. Mpindi JP, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, Hirasawa A, Kangaspeska S, Wennerberg K, Kallioniemi O, Aittokallio T. Consistency in drug response profiling. Nature 2016; 540 (7631): E5-E6. doi: 10.1038 / nature20171.